Janssen Pharmaceuticals
Janssen Pharmaceuticals (United States) has no DMF, CEP or site registration linked in our records. 18 FDA enforcement records are linked to it.
Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records
Cite as: PharmaTek, “Janssen Pharmaceuticals: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/janssen-pharmaceuticals
Overview
Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, is dedicated to addressing and solving some of the most important unmet medical needs of our time. It specializes in medicines for a variety of diseases and conditions, focusing on therapeutic areas like oncology, immunology, and neuroscience.
Core services & business areas
Therapeutic areas
FDA compliance signals
18 FDA enforcement records linked to this company.
- 4832026-09-25
Failure to comply with REMS Elements to Assure Safe Use (ETASU) D
- 4832024-09-27
Failure to comply with REMS Implementation System
- 4832023-12-14
Scientifically sound laboratory controls
- 4832023-12-14
Cleaning / Sanitizing / Maintenance
- 4832023-12-14
Training , Education , Experience overall
- recall — Class II2018-11-14
Labeling: Incorrect Instructions; Instructions included for use with the Veridate dispenser contained instructions for the Dialpak dispenser.
- recall — Class II2018-11-14
Labeling: Incorrect Instructions; Instructions included for use with the Veridate dispenser contained instructions for the Dialpak dispenser.
- 4832016-09-21
Late submission of 15-day report
- 4832016-09-21
Failure to develop written procedures
- recall — Class II2015-05-20
Subpotent Drug
- recall — Class II2014-08-13
Non-Sterility: Janssen is recalling one lot of Risperdal CONSTA (risperiDONE) due to a sterility failure in a stability sample
- 4832014-02-12
Failure to develop written procedures
- 4832014-02-12
Late submission of 15-day report
- 4832011-07-21
Failure to develop written procedures
- warning_letter2010-09-14
FDA Warning Letter (drug product)
- 4832009-07-20
Failure to develop written procedures
- 4832009-07-20
Failure by applicant to report ADE
- warning_letter2008-11-24
FDA Warning Letter (drug product)
Is this Janssen Pharmaceuticals?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.
Need suppliers found and checked?
The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.